Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare and progressively debilitating disease characterized by the accumulation of misfolded transthyretin (TTR) protein in the heart tissue 4.
This buildup forms amyloid fibrils, leading to the stiffening and weakening of the heart muscle, ultimately resulting in heart failure 4.
There are two primary classifications of ATTR-CM: hereditary (hATTR-CM), which arises from inherited genetic mutations in the TTR gene, and wild-type (wATTR-CM), which is associated with aging and occurs without a known genetic cause 4.
The symptoms of ATTR-CM can be varied and often mimic those of other cardiac conditions, making accurate and timely diagnosis challenging 4.
Common symptoms include shortness of breath, swelling in the legs and ankles (edema), persistent fatigue, and irregular heart rhythms (arrhythmias) 4. Historically, effective treatments for ATTR-CM have been limited, resulting in a poor prognosis for affected individuals if the disease goes untreated 5.
The average survival time for individuals with untreated ATTR-CM can range from 2 to 3.5 years following diagnosis 5. This underscores the significant unmet medical need for therapies that can effectively slow or halt the progression of this devastating disease and ultimately improve the outcomes for patients 1.
The fact that the symptoms of ATTR-CM often overlap with other more prevalent heart conditions suggests a potential for initial misdiagnosis or delays in recognizing the underlying cause 5. This highlights the critical importance of raising awareness among healthcare professionals to ensure that ATTR-CM is considered in the differential diagnosis, especially in patients presenting with heart failure and other suggestive signs.
Furthermore, studies have indicated that individuals of Black ethnicity have a higher likelihood of developing the familial form of ATTR 4. This observation points to potential health disparities associated with this disease and emphasizes the need for tailored diagnostic and treatment strategies that consider the diverse genetic risk factors across different populations.
Vutrisiran, known commercially as Amvuttra, represents a novel approach to treating ATTR-CM through its mechanism of action as a small interfering RNA (siRNA) therapy 1. This innovative therapeutic works by specifically targeting and degrading the messenger RNA (mRNA) of the transthyretin (TTR) protein within the liver 1.
The liver is the primary site of TTR protein production, and in ATTR amyloidosis, it is the misfolded forms of this protein that aggregate to form amyloid deposits in various tissues, including the heart. Vutrisiran harnesses the natural cellular process of RNA interference (RNAi) to achieve this targeted reduction in TTR production 12.
Upon administration via subcutaneous injection, vutrisiran enters the hepatocytes, the liver cells responsible for TTR synthesis 12. Within these cells, the siRNA component of vutrisiran is incorporated into a multi-protein complex called the RNA-induced silencing complex (RISC) 12. The siRNA then unwinds, and one of its strands, the guide strand, binds to the complementary sequence in the TTR mRNA molecule 12.
This binding triggers the cleavage and subsequent degradation of the TTR mRNA by the endonuclease activity associated with RISC 12. As a result, the levels of TTR mRNA are significantly diminished, leading to a corresponding decrease in the synthesis of both the normal (wild-type) and mutated forms of the TTR protein 1.
This reduction in the available TTR protein is crucial as it directly lowers the amount of misfolded protein that can contribute to the formation and accumulation of amyloid deposits in the heart, thereby addressing the underlying cause of ATTR amyloidosis 1. Vutrisiran utilizes a sophisticated delivery platform involving conjugation with N-acetylgalactosamine (GalNAc) 11.
This modification enhances the uptake of the siRNA by liver cells, which express asialoglycoprotein receptors that bind to GalNAc, allowing for efficient and targeted delivery. This targeted delivery system enables subcutaneous administration of the drug just once every three months 11.
The use of siRNA technology offers a direct and highly specific way to lower TTR protein levels, contrasting with the mechanism of TTR stabilizers that work by preventing the breakdown and misfolding of the existing protein.
The less frequent subcutaneous administration, facilitated by the GalNAc conjugate, offers a potentially more convenient treatment schedule for patients compared to daily oral medications, which could improve long-term adherence.
The FDA approval of vutrisiran for ATTR-CM was primarily based on the positive results from the HELIOS-B clinical trial 1. This was a global, randomized, double-blind, and placebo-controlled study that enrolled 655 adult patients diagnosed with either wild-type or hereditary ATTR-CM 1.
The primary objective of the trial was to evaluate the efficacy of vutrisiran in reducing the risk of all-cause mortality and recurrent cardiovascular events, a composite endpoint that reflects the major clinical consequences of the disease 1.
The study demonstrated that patients receiving subcutaneous injections of vutrisiran every three months experienced a statistically significant 28% reduction in the risk of this composite endpoint compared to those receiving a placebo 1.
Notably, a subgroup analysis revealed an even more pronounced benefit in patients who were not already taking tafamidis, another approved therapy for ATTR-CM. In this monotherapy population, vutrisiran treatment resulted in a 33% reduction in the risk of mortality and recurrent cardiovascular events during the double-blind treatment period, with this reduction extending to 35% for all-cause mortality alone when followed up to 42 months 1.
Furthermore, the study showed a significant 35% reduction in all-cause mortality in the monotherapy group over 42 months 14. Consistent benefits were observed across various key patient subgroups, including those who were receiving background therapy with tafamidis 14. In this subgroup, vutrisiran demonstrated a notable 41% reduction in all-cause mortality at 42 months compared to placebo 14.
Beyond these primary and secondary efficacy outcomes, patients treated with vutrisiran also showed preservation of their functional capacity and reported improvements in their quality of life compared to the placebo group 1. Additionally, the trial observed early improvements in key cardiac biomarkers, such as N-terminal pro-B-type natriuretic peptide (NT-proBNP) and troponin I, which are indicative of reduced cardiac stress and damage 1.
The safety profile of vutrisiran in the HELIOS-B trial was also encouraging, with the incidence of cardiac adverse events being similar or even lower in the vutrisiran treatment arm compared to the placebo arm 14.
These robust findings from the HELIOS-B study strongly suggest that vutrisiran has the potential to become a new standard of care in the treatment paradigm for ATTR-CM, offering significant clinical benefits in terms of survival and cardiovascular outcomes. The substantial reductions in mortality and cardiovascular events observed in the trial provide compelling evidence of vutrisiran's clinical effectiveness in managing ATTR-CM.
The fact that the treatment benefit was even greater in patients who were not concurrently taking tafamidis suggests that vutrisiran may be particularly impactful as an initial therapy for ATTR-CM or in individuals for whom TTR stabilization alone may not be sufficient.
While the study also indicated a trend toward additive efficacy when vutrisiran was used in conjunction with tafamidis, further research will be valuable in defining the optimal strategies for combining or sequencing these different therapeutic approaches.
The observed improvements in cardiac biomarkers further reinforce the clinical benefit of vutrisiran by demonstrating its positive effects on underlying cardiac pathology. These molecular-level changes support the notion that vutrisiran has a genuine disease-modifying impact in ATTR-CM.
The therapeutic landscape for ATTR-CM now includes vutrisiran alongside two other FDA-approved medications: tafamidis and acoramidis. Understanding the nuances of each therapy, particularly their mechanisms of action, administration, and efficacy profiles, is crucial for informed clinical decision-making.
Tafamidis (marketed as Vyndaqel and Vyndamax) operates through a different mechanism than vutrisiran. Tafamidis acts as a stabilizer of the transthyretin tetramer, preventing it from dissociating into monomers, which are the precursors to misfolded proteins and amyloid fibril formation 2. In contrast, vutrisiran works upstream by silencing the TTR gene, thus reducing the production of both the normal and mutated TTR protein 2.
Another key difference lies in their administration: vutrisiran is administered as a subcutaneous injection once every three months by a healthcare professional 1, whereas tafamidis is an oral medication taken once daily 11.
Assessing the comparative efficacy of these two therapies directly is challenging due to variations in the design and patient populations of their respective pivotal trials, as well as the fact that tafamidis was already available and used by some patients in the vutrisiran trial 20.
The ATTR-ACT trial demonstrated that tafamidis reduced all-cause mortality by 33% over a 30-month period 17. In the HELIOS-B trial, vutrisiran showed a 35% reduction in all-cause mortality in the monotherapy group over 42 months 14.
An indirect treatment comparison conducted in patients with hATTR-PN suggested that vutrisiran may have greater efficacy than tafamidis in improving polyneuropathy symptoms and health-related quality of life 22. Furthermore, vutrisiran has demonstrated a reduction in recurrent cardiovascular events in patients with ATTR-CM 20.
It is also important to note that treatment with vutrisiran leads to a decrease in serum Vitamin A levels, necessitating vitamin supplementation for patients on this therapy 1. The availability of two distinct mechanisms of action, TTR silencing with vutrisiran and TTR stabilization with tafamidis, offers clinicians a broader range of therapeutic strategies to consider based on individual patient characteristics and disease presentation.
This allows for a more personalized approach to managing ATTR-CM. While direct comparative data is limited, the existing evidence suggests that both therapies offer significant benefits in reducing mortality.
The potential advantages of vutrisiran in areas such as cardiovascular events and polyneuropathy, as indicated by indirect comparisons, warrant further investigation. The practical consideration of Vitamin A supplementation with vutrisiran is an important aspect of patient management that clinicians must address.
Acoramidis (marketed as Attruby) is the third approved therapy for ATTR-CM. Similar to tafamidis, acoramidis is a transthyretin stabilizer 2. It selectively binds to the thyroxine binding sites on the TTR protein, slowing the dissociation of the tetramer into monomers, which is the rate-limiting step in amyloidogenesis 26.
Acoramidis is described as a high-affinity stabilizer that aims for near-complete TTR stabilization and mimics the action of a naturally occurring protective mutation of the TTR gene 27. While vutrisiran is administered via quarterly subcutaneous injection 1, acoramidis is an oral medication taken twice daily 11. Direct comparisons between vutrisiran and acoramidis are also not available due to the lack of head-to-head clinical trials 21.
The ATTRibute-CM trial demonstrated that acoramidis significantly improved a composite primary endpoint consisting of all-cause mortality, cardiovascular-related hospitalization, change in NT-proBNP levels, and change in the 6-minute walk distance compared to placebo 24. At 30 months, acoramidis showed a 42% reduction in the composite of all-cause mortality and cardiovascular hospitalizations compared to placebo, with this benefit extending to a 48.2% reduction with continuous use through 42 months 29.
In comparison, vutrisiran demonstrated a 28% reduction in the risk of all-cause mortality and recurrent cardiovascular events in the overall population in the HELIOS-B trial 1. Acoramidis has also been shown to improve functional and biomarker endpoints in patients with ATTR-CM 24. Some data suggest that acoramidis treatment leads to an increase in serum TTR levels, likely due to its stabilizing effect on the protein 26.
Acoramidis was generally well-tolerated in clinical trials, with some patients experiencing gastrointestinal adverse reactions 26. While both tafamidis and acoramidis function as TTR stabilizers, acoramidis is believed to have a higher potency and achieve near-complete stabilization, which could potentially lead to greater clinical benefits.
The choice between the less frequent injection of vutrisiran and the twice-daily oral administration of acoramidis may depend on patient preference and lifestyle considerations. The observation that acoramidis increases serum TTR levels is a consequence of its mechanism of action, preventing the breakdown of the protein and its subsequent clearance, which can be a useful indicator of drug activity.
The annual list price for vutrisiran is a substantial $477,000, based on the current cost for its use in treating hATTR-PN. This price point is higher than the initial list price of tafamidis, which was approximately $268,000 per year upon its approval.
Acoramidis is priced at around $244,000 annually 34. These high costs have raised concerns about the cost-effectiveness of these therapies.
The Institute for Clinical and Economic Review (ICER) has previously assessed tafamidis and suggested that its price would need to be significantly reduced to meet commonly accepted cost-effectiveness thresholds, recommending a price range of $13,600 to $39,000 per year for TTR stabilizers 34.
ICER gave the HELIOS-B data for vutrisiran an "A" rating, indicating a high certainty of substantial net health benefit compared to no disease-specific therapy 36.
However, a specific value assessment for vutrisiran itself was not available in the provided materials. Alnylam has stated that a significant majority (99%) of patients using vutrisiran for hATTR-PN have insurance coverage, with most paying $0 out-of-pocket, and the company anticipates similar broad coverage for ATTR-CM.
To support patient access, Alnylam offers a comprehensive patient assistance program called Alnylam Assist 3. This program includes a copay program for eligible commercially insured patients, a Patient Assistance Program (PAP) that provides vutrisiran at no cost to qualifying uninsured or underinsured individuals, and assistance with navigating insurance coverage, including a Quick Start program to provide initial doses during coverage delays 3.
Similarly, Pfizer offers patient assistance programs for tafamidis through VyndaLink and RxPathways 42. These programs provide copay support for commercially insured patients and assistance for those with limited or no insurance.
BridgeBio also has a patient support program called ForgingBridges for acoramidis, offering a patient prescription assistance program, copay assistance, and a QuickStart program 47.
Despite the availability of these patient assistance programs, the high list prices of vutrisiran and other ATTR-CM therapies remain a significant concern for the overall affordability and sustainability of healthcare.
While these programs can help individual patients manage out-of-pocket expenses, the substantial cost burden on payers and the potential limitations of these programs need to be considered. The expectation of broad insurance coverage for vutrisiran suggests a proactive effort by the manufacturer to ensure patient access, recognizing the clinical value demonstrated in the HELIOS-B trial.
The consistent presence of patient assistance programs across all approved ATTR-CM therapies underscores the industry's acknowledgment of the financial challenges associated with treating this rare and costly disease.
The field of ATTR-CM therapeutics continues to evolve with several promising therapies in development. Eplontersen, another siRNA therapy developed by Ionis Pharmaceuticals, is currently undergoing evaluation in the Phase III CARDIO-TTRansform trial for the treatment of ATTR-CM.
This therapy is administered via a monthly subcutaneous injection and is anticipated to potentially become available for ATTR-CM patients in approximately 18 months. Notably, eplontersen has already received FDA approval for the treatment of hATTR-PN under the brand name Wainua 49.
The CARDIO-TTRansform trial is considered the largest study conducted to date in ATTR-CM, reflecting the significant interest in developing effective treatments for this condition 50. Beyond siRNA therapies, other innovative approaches are being explored in clinical trials.
These include NTLA-2001, a CRISPR-Cas9 gene editing therapy that aims to knock out the TTR gene, offering the potential for a more definitive treatment for hereditary forms of the disease 9.
Additionally, fibril depleters like ALXN2220 and coramitug, as well as monoclonal antibodies targeting misfolded TTR protein, are also in various stages of clinical investigation 9. These diverse therapeutic strategies, along with ongoing efforts to improve diagnostic tools, indicate a dynamic and rapidly advancing landscape for the treatment of both ATTR-CM and other forms of cardiac amyloidosis 51.
The emergence of multiple therapies with different mechanisms of action in the ATTR-CM pipeline signifies a positive trend towards offering a wider array of treatment options for patients.
The fact that eplontersen, like vutrisiran, utilizes siRNA technology highlights the potential of this approach in managing ATTR amyloidosis. The different dosing schedules (quarterly for vutrisiran vs. monthly for eplontersen) may offer varying advantages in terms of patient convenience or therapeutic profiles.
The development of gene editing technologies like CRISPR represents a groundbreaking approach that could potentially revolutionize the treatment of hereditary ATTR by addressing the root genetic cause of the disease.
In conclusion, the FDA approval of vutrisiran (Amvuttra) represents a significant milestone in the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).
As the first RNAi therapeutic approved for this indication, vutrisiran expands the treatment options beyond TTR stabilizers by offering a novel mechanism of action that reduces the production of the amyloidogenic TTR protein.
The clinical benefits demonstrated in the pivotal HELIOS-B trial, including significant reductions in mortality and cardiovascular events, underscore the potential of vutrisiran to improve outcomes for patients with this devastating condition.
The availability of two distinct classes of disease-modifying treatments, TTR stabilizers and TTR silencers, provides clinicians with more tools to personalize treatment strategies based on individual patient needs.
While the cost of vutrisiran is substantial, the existence of patient assistance programs aims to improve access for eligible individuals.
Looking ahead, the ATTR-CM therapeutic landscape is poised for further advancements with emerging therapies like eplontersen and innovative approaches such as gene editing holding great promise for the future.
Vutrisiran marks a significant step forward in the ongoing efforts to effectively manage ATTR-CM and improve the lives of those affected by this rare and progressive disease.
Table 1: Comparison of Approved ATTR-CM Therapies
Feature | Vutrisiran (Amvuttra) | Tafamidis (Vyndaqel/Vyndamax) | Acoramidis (Attruby) |
Mechanism of Action | TTR mRNA silencing, reduces TTR protein production | Stabilizes TTR tetramer, prevents misfolding | Stabilizes TTR tetramer, aims for near-complete stabilization |
Administration | Subcutaneous injection every 3 months (HCP administered) | Oral capsule once daily | Oral tablet twice daily |
Key Efficacy Findings | 28% reduction in mortality/CV events (overall); 35% mortality reduction (monotherapy at 42 months) | 33% reduction in all-cause mortality over 30 months | 42% reduction in mortality/CV hospitalizations at 30 months; 48.2% reduction with continuous use at 42 months |
Notable Side Effects | Injection site reactions, fatigue, arthralgia, dyspnea | Headache, UTI, peripheral edema, GI issues | Diarrhea, upper abdominal pain, increased serum creatinine |
Vitamin A Supplementation | Yes | No | No |
Table 2: Summary of Patient Assistance Programs for Approved ATTR-CM Therapies
Drug Name | Manufacturer | Program Name(s) | Types of Assistance Offered | Contact Information |
Vutrisiran (Amvuttra) | Alnylam | Alnylam Assist® | Copay program, Patient Assistance Program (PAP), Quick Start program, insurance support | 1-833-256-2748; www.AlnylamAssist.com |
Tafamidis (Vyndaqel/Vyndamax) | Pfizer | VyndaLink™, Pfizer RxPathways | Copay savings program, Patient Assistance Program, benefits verification, prior authorization support | 1-888-222-8475; www.VyndaLink.com |
Acoramidis (Attruby) | BridgeBio | ForgingBridges | Patient Assistance Program (PAP), copay assistance, QuickStart program, personalized support for insurance navigation | 1-888-55-BRIDGE (1-888-552-7434); ForgingBridges.com |
Works cited
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular, accessed March 23, 2025, https://investors.alnylam.com/press-release?id=28831
FDA Approves Amvuttra™ (vutrisiran) for ATTR-CM, accessed March 23, 2025, https://arci.org/amvuttra-attr-cm-approval/
Financial Assistance & Support | AMVUTTRA® (vutrisiran), accessed March 23, 2025, https://www.amvuttra.com/attr-cm/resources-support/financial-assistance-support
Transthyretin Amyloidosis (ATTR-CM): Types, Causes, Treatment - Cleveland Clinic, accessed March 23, 2025, https://my.clevelandclinic.org/health/diseases/17855-amyloidosis-attr
ATTR-CM: Causes, symptoms, and treatment options - Medical News Today, accessed March 23, 2025, https://www.medicalnewstoday.com/articles/transthyretin-amyloid-cardiomyopathy
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - American Heart Association, accessed March 23, 2025, https://www.heart.org/en/health-topics/cardiomyopathy/what-is-cardiomyopathy-in-adults/transthyretin-amyloid-cardiomyopathy-attr-cm
Transthyretin amyloid cardiomyopathy (ATTR-CM) - World Heart Federation, accessed March 23, 2025, https://world-heart-federation.org/world-heart-day/wp-content/uploads/sites/4/ATTR-CM-Infographic-World-Heart-Day-FINAL.pdf
Transthyretin Amyloidosis (ATTR) - Pfizer, accessed March 23, 2025, https://www.pfizer.com/disease-and-conditions/attr-amyloidosis
Study Reveals Exciting New Treatment for Cardiac Amyloidosis with Cardiomyopathy, accessed March 23, 2025, https://www.medstarhealth.org/blog/cardiac-amyloidosis-treatment-research
Alnylam Builds ATTR-CM Case for Vutrisiran With Strong Phase III Survival Data - BioSpace, accessed March 23, 2025, https://www.biospace.com/drug-development/alnylam-builds-attr-cm-case-for-vutrisiran-with-strong-phase-iii-survival-data
Vutrisiran - Wikipedia, accessed March 23, 2025, https://en.wikipedia.org/wiki/Vutrisiran
What is the mechanism of Vutrisiran? - Patsnap Synapse, accessed March 23, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-vutrisiran
Vutrisiran: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed March 23, 2025, https://go.drugbank.com/drugs/DB16699
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran in Patients with A, accessed March 23, 2025, https://investors.alnylam.com/press-release?id=28411
Treating amyloid cardiomyopathy (ATTR-CM) with tafamidis - Norton Healthcare Provider, accessed March 23, 2025, https://nortonhealthcareprovider.com/news/attr-cm-tafamidis/
How does VYNDAMAX® (tafamidis) Work? | Safety Info, accessed March 23, 2025, https://www.vyndamax.com/how-vyndamax-works
Tafamidis - StatPearls - NCBI Bookshelf, accessed March 23, 2025, https://www.ncbi.nlm.nih.gov/books/NBK574508/
Tafamidis: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed March 23, 2025, https://go.drugbank.com/drugs/DB11644
Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis - PMC - PubMed Central, accessed March 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4919130/
The effectiveness and value of disease-modifying therapies for transthyretin amyloid cardiomyopathy: A summary from the Institute for Clinical and Economic Review's Midwest Comparative Effectiveness Public Advisory Council, accessed March 23, 2025, https://www.jmcp.org/doi/10.18553/jmcp.2025.31.3.323
The effectiveness and value of disease-modifying therapies for transthyretin amyloid cardiomyopathy, accessed March 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11871155/
Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy - PubMed, accessed March 23, 2025, https://pubmed.ncbi.nlm.nih.gov/37219406/
Outpatient Worsening Heart Failure in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the HELIOS-B Trial | JACC, accessed March 23, 2025, https://www.jacc.org/doi/10.1016/j.jacc.2024.11.015
BridgeBio Builds ATTR-CM Case for Acoramidis with Promising Phase III Data - BioSpace, accessed March 23, 2025, https://www.biospace.com/bridgebio-builds-attr-cm-case-for-acoramidis-with-promising-phase-iii-data
Effect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) Substudy - PMC, accessed March 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11643112/
ATTRUBY (acoramidis) - accessdata.fda.gov, accessed March 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216540s000lbl.pdf
Acoramidis for symptomatic transthyretin amyloid cardiomyopathy - Health Technology Briefing July 2023, accessed March 23, 2025, https://www.io.nihr.ac.uk/wp-content/uploads/2023/07/24010-Acoramidis-for-Transthyretin-Amyloid-Cardiomyopathy-V1.0-JUL2023-NON-CONF.pdf
Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy - PubMed, accessed March 23, 2025, https://pubmed.ncbi.nlm.nih.gov/38197816/
Acoramidis Sustains Benefits in Patients With ATTR-CM in Open-Label Extension Study, accessed March 23, 2025, https://www.ajmc.com/view/acoramidis-sustains-benefits-in-patients-with-attr-cm-in-open-label-extension-study
BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension, accessed March 23, 2025, https://bridgebio.com/news/bridgebio-shares-data-on-serum-ttr-increase-when-switching-participants-from-placebo-and-tafamidis-to-acoramidis-in-attribute-cm-and-its-open-label-extension/
Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy - JACC Journals, accessed March 23, 2025, https://www.jacc.org/doi/abs/10.1016/j.jacc.2024.11.042
Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy - ATTRibute-CM, accessed March 23, 2025, https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2023/08/24/02/29/attribute-cm
Increase in serum TTR levels observed with acoramidis treatment in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): insights from ATTRibute-CM and its open-label extension | European Heart Journal | Oxford Academic, accessed March 23, 2025, https://academic.oup.com/eurheartj/article/45/Supplement_1/ehae666.2088/7836837
FDA Approves First 'Near-Complete' Stabilizer to Treat ATTR Cardiomyopathy | tctmd.com, accessed March 23, 2025, https://www.tctmd.com/news/fda-approves-first-near-complete-stabilizer-treat-attr-cardiomyopathy
Institute for Clinical and Economic Review Publishes Final Evidence Report on Treatments for Transthyretin Amyloid Cardiomyopathy - ICER, accessed March 23, 2025, https://icer.org/news-insights/press-releases/icer-publishes-final-evidence-report-attr-cm/
ICER raises cost-effective price for Pfizer's ATTR drug in final analysis but still calls for hefty discount - Fierce Pharma, accessed March 23, 2025, https://www.fiercepharma.com/pharma/icer-raises-cost-effective-price-pfizers-attr-drug-final-analysis-still-calls-hefty-discount
Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy - PubMed, accessed March 23, 2025, https://pubmed.ncbi.nlm.nih.gov/32078382/
Institute for Clinical and Economic Review Publishes Evidence Report on Treatments for Transthyretin Amyloid Cardiomyopathy - ICER, accessed March 23, 2025, https://icer.org/news-insights/press-releases/institute-for-clinical-and-economic-review-publishes-evidence-report-on-treatments-for-transthyretin-amyloid-cardiomyopathy/
Alnylam Assist® | AMVUTTRA® (vutrisiran), accessed March 23, 2025, https://www.amvuttra.com/resources-support/alnylam-assist
Financial Assistance | AMVUTTRA® (vutrisiran), accessed March 23, 2025, https://www.alnylamassist.com/amvuttra/financial-assistance
Starting Treatment | AMVUTTRA® (vutrisiran), accessed March 23, 2025, https://www.amvuttrahcp.com/getting-started
VYNDAQEL® OR VYNDAMAX® (tafamidis meglumine or tafamidis) Patient information | Pfizer Medical Information - US, accessed March 23, 2025, https://www.pfizermedicalinformation.com/patient/vyndaqel-or-vyndamax
Patients and Caregivers | VyndaLink™, accessed March 23, 2025, https://www.vyndalink.com/patient
Paying for VYNDAMAX® (tafamidis) | Safety Info - Pfizer For Professionals, accessed March 23, 2025, https://vyndamax.pfizerpro.com/access-and-support/paying-for-vyndamax
How to Access VYNDAMAX® (tafamidis) for Your Patients | Safety Info, accessed March 23, 2025, https://vyndamax.pfizerpro.com/access-and-support/accessing-vyndamax
Financial Support | Patients and Caregivers | VyndaLink™, accessed March 23, 2025, https://www.vyndalink.com/patient/financial-support
Attruby™ (acoramidis), accessed March 23, 2025, https://arci.org/wp-content/uploads/2024/11/Attruby-Acoramidis-Infosheet.pdf
Attruby™ Patient Support Program - Financial Help & More, accessed March 23, 2025, https://attruby.com/patient-support-program
Wainua (eplontersen) granted first-ever regulatory approval in the US for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis - AstraZeneca, accessed March 23, 2025, https://www.astrazeneca.com/media-centre/press-releases/2023/wainua-eplontersen-granted-first-ever-regulatory-approval-us-treatment-of-adults-with-polyneuropathy-hereditary-transthyretin-mediated-amyloidosis.html
Eplontersen Gains FDA Fast Track Designation for Transthyretin-Mediated Amyloid Cardiomyopathy - NeurologyLive, accessed March 23, 2025, https://www.neurologylive.com/view/eplontersen-gains-fda-fast-track-designation-transthyretin-mediated-amyloid-cardiomyopathy
New therapies to treat cardiac amyloidosis - PubMed, accessed March 23, 2025, https://pubmed.ncbi.nlm.nih.gov/39819772/
Future Directions in Cardiac Amyloidosis - PMC, accessed March 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8932374/
